Clinical Trials - BCRX

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT06539507A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725RECRUITINGPHASE12024-09-262026-032026-03
NCT06100900Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)COMPLETEDPHASE12023-10-242024-12-112024-12-11
NCT05741346Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal HemoglobinuriaTERMINATEDPHASE22023-01-182025-01-312025-01-31
NCT05453968Berotralstat Treatment in Children With Hereditary AngioedemaACTIVE_NOT_RECRUITINGPHASE32022-10-252027-022024-09-11
NCT05162066Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)TERMINATEDPHASE22022-02-182022-09-232022-09-23
NCT05116774BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyTERMINATEDPHASE22021-12-062023-09-142023-09-14
NCT05116787BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor TherapyTERMINATEDPHASE22021-10-262023-09-182023-09-18
NCT04933721Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat StudiesACTIVE_NOT_RECRUITINGPHASE32021-07-232031-082031-08
NCT04702568A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)TERMINATEDPHASE22020-12-182023-10-042023-10-04
NCT03891420A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19TERMINATEDPHASE12020-04-092021-04-302021-01-31
NCT04330534First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNHCOMPLETEDPHASE1, PHASE22020-03-032021-01-252020-11-11
NCT03873116Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in JapanCOMPLETEDPHASE32018-12-272021-07-082021-07-08
NCT03800173A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430COMPLETEDPHASE12018-12-102019-04-302019-04-30
NCT03472040A Long Term Safety Study of BCX7353 in Hereditary AngioedemaCOMPLETEDPHASE2, PHASE32018-02-162022-04-272022-04-27
NCT03485911Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAECOMPLETEDPHASE32018-02-062022-04-062019-04-10
NCT03240133Study of BCX7353 as a Treatment for Attacks of Hereditary AngioedemaCOMPLETEDPHASE22017-07-312019-01-292019-01-29
NCT03202784A Relative Bioavailability Study of Two Formulations of BCX7353COMPLETEDPHASE12017-02-272017-09-302017-08-01
NCT03136237A Drug-Drug Interaction Study to Evaluate Drug Transporter InteractionsCOMPLETEDPHASE12017-02-172017-08-152017-08-15
NCT02870972Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary AngioedemaCOMPLETEDPHASE22016-082017-082017-08
NCT02819102An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe SubstratesCOMPLETEDPHASE12016-032016-062016-06
NCT02635724Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated InfluenzaCOMPLETEDPHASE32015-122018-092018-04
NCT02670720Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary AngioedemaTERMINATEDPHASE32015-122016-022016-02
NCT02448264First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese VolunteersCOMPLETEDPHASE12015-052015-122015-11
NCT02369159Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated InfluenzaCOMPLETEDPHASE32015-03-112020-05-142019-10-28
NCT02319772A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430COMPLETEDPHASE12014-122016-042016-03
NCT0230362612-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksCOMPLETEDPHASE2, PHASE32014-112016-012016-01
NCT02218294Study to Determine How BCX4161 is Metabolized and Eliminated by the BodyCOMPLETEDPHASE12014-082014-092014-09
NCT02125162A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161COMPLETEDPHASE12014-042014-072014-07
NCT01984788Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAECOMPLETEDPHASE22013-112014-052014-05
NCT01407874A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal InsufficiencyCOMPLETEDPHASE22011-092012-072012-07
NCT01265264Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to AllopurinolCOMPLETEDPHASE22010-122013-022012-07
NCT01224795A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.TERMINATEDPHASE32010-102010-112010-11
NCT01129648Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/GoutCOMPLETEDPHASE22010-052010-112010-11
NCT00958776A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to InfluenzaTERMINATEDPHASE32009-112013-102012-11
NCT00957996Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected InfluenzaCOMPLETEDPHASE32009-102011-082010-10
NCT00985127Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With GoutCOMPLETEDPHASE22009-092010-092010-09
NCT00705406A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute InfluenzaCOMPLETEDPHASE22008-072009-102009-04
NCT00640523Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)COMPLETEDPHASE22008-032011-112010-11
NCT00610935Intramuscular Peramivir in Subjects With Uncomplicated Acute InfluenzaTERMINATEDPHASE32008-012008-022008-02
NCT00453999Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening InfluenzaCOMPLETEDPHASE22007-072009-082008-09
NCT00501735Forodesine in the Treatment of Cutaneous T-Cell LymphomaCOMPLETEDPHASE22007-072011-122010-07
NCT00419263Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.COMPLETEDPHASE22007-012007-092007-09
NCT00419081Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment RegimensTERMINATEDPHASE22006-072007-032007-03
NCT00289549Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)COMPLETEDPHASE22005-062009-012009-01
NCT00289562Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic LeukemiaCOMPLETEDPHASE1, PHASE22004-092007-122007-12
NCT00095381Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell LeukemiaCOMPLETEDPHASE22004-032007-122007-03
NCT00035022Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or LymphomasCOMPLETEDPHASE1, PHASE22001-082004-03
NCT00486980Intramuscular Peramivir for the Treatment of Uncomplicated InfluenzaWITHDRAWNPHASE3
NCT00002237A Study of Peldesine (BCX-34) in HIV-Infected PatientsCOMPLETEDPHASE1